Recent years have witnessed impressive advances in our understanding of iron metabolism. A number of studies of iron disorders and of their animal models have provided landmark insights into the mechanisms of iron trafficking, distribution and homeostatic regulation, the latter essential to prevent both iron deficiency and iron excess. Our perception of iron metabolism has been completely changed by an improved definition of cellular and systemic iron homeostasis, of the molecular pathogenesis of iron disorders, the fine tuning of the iron hormone hepcidin by activators and inhibitors and the dissection of the components of the hepcidin regulatory pathway. Important for haematology, the crosstalk of erythropoiesis, the most important iron consumer, and the hepcidin pathway has been at least partially clarified. Novel potential biomarkers are available and novel therapeutic targets for iron-related disorders have been tested in murine models. These preclinical studies provided proofs of principle and are laying the ground for clinical trials. Understanding iron control in tissues other than erythropoiesis remains a challenge for the future.
Advances in understanding cell and systemic iron homeostasis have revolutionised iron physiology in the last 20 years. Iron metabolism is a dynamic field of research: every year, new discoveries not only allow better definition of the physiological role of iron in mammals but also influence the therapeutic approaches to iron and iron-related erythroid disorders.
A major step forward was the discovery of the hepcidinferroportin axis (Nemeth et al, 2004) . Hepcidin is the central hub of iron homeostasis that integrates multiple signals to control iron release to plasma according to the body needs (Hentze et al, 2010) . This landmark breakthrough was paralleled by advances in the understanding of iron trafficking and cellular regulation and by recent discoveries about new biological functions of iron. Besides increasing our knowledge on iron physiology, these studies have identified numerous novel therapeutic targets. At the same time, animal models of iron disorders have been developed and now provide the tools for proof of principle studies and for preclinical testing of the efficacy of targeted therapeutic approaches. Some specific compounds have reached the stage of clinical trials and innovative therapeutic strategies are beginning to be clinically translated for the treatment of iron disorders.
Notwithstanding these impressive advances, the iron regulatory system is still incompletely understood and new discoveries continuously challenge our current knowledge and the proposed models. This review focuses on the new findings in iron metabolisms that are relevant to haematology, including iron trafficking, iron homeostasis, the crosstalk between iron and erythropoiesis and the clinical implications of the new insights.
Iron trafficking

Novel iron transporters and novel functions
To acquire iron for multiple biological functions and at the same time to avoid its harmful excess, cells have mechanisms for iron uptake, storage and export, as exemplified in Fig. 1 .
The most important cell iron importer, transferrin receptor (TFR1, also termed TFRC), is a ubiquitous protein encoded by the transferrin receptor (TFRC, also termed TRF1) gene (Fig. 1) . TFR1 is essential for erythroid tissue and the central nervous system as Tfrc (also termed Tfr1) knock out (KO) mice die at the embryonic stage because of severe anaemia and abnormal brain development (Levy et al, 1999) . Selective Tfrc inactivation in different tissues showed that TFR1 is essential also for adult cardiomyocytes (Xu et al, 2015) , skeletal muscle cells , gut development (Chen et al, 2015) , and dopaminergic neurons (Matak et al, 2016) .
TFRC mutations are not reported as a cause of genetic forms of anaemia. Instead, the single homozygous mutation in so far described, a tyrosine to histidine (Y20H) substitution in the intracellular internalization motif of the receptor, causes a form of primary combined immunodeficiency [Online Mendelian Inheritance in Man (OMIM) entry 616740). This may indicate that an essential role of TFR1 is providing iron to lymphocytes. While in some patients immunodeficiency was so severe that bone marrow transplantation was required, anaemia was, surprisingly, absent or mild (Jabara et al, 2016) . The normal internalization of TFR1 Y20H in erythroid cells was dependent on the signalling motif of Six-Transmembrane Epithelial Antigen of Prostate 3 (STEAP3), the metalloreductase that cooperates with TFR1 in the endosomal compartment (Jabara et al, 2016) . The duodenal iron importer divalent metal transporter 1 (DMT1, also termed SLC11A2, encoded by the SLC11A2 gene) transports several divalent metals. The importance of intestinal DMT1 on the apical surface of enterocytes has long been recognized, because rodents with mutated Dmt1 (Slc11a2) have severe iron deficiency (Fleming et al, 1998) . In humans, who, unlike rodents, are able to absorb haem iron, mutant SLC11A2 affects mostly the erythroblasts rendering them unable to transfer iron from endosomes to mitochondria (Iolascon et al, 2006) . In the gut DMT1 is under the control of hypoxia inducible factor 2a (HIF2-a, also termed EPAS1, encoded by the EPAS1 gene), which accounts for its basal production in the hypoxic environment of the gut and its increase in systemic hypoxia. In conjunction with the suppression of hepcidin in hypoxia, enhanced iron acquisition from the lumen translates into high iron export by ferroportin (also termed SLC40A1, encoded by the SLC40A1 gene) on the basolateral membrane (Mastrogiannaki et al, 2013) .
In pathological conditions, the zinc transporter protein 14 (ZIP14) may mediate the uptake of iron (Fig. 1 ) in hepatocytes and pancreatic acinar cells. ZIP14 imports Non-Transferrin-Bound-Iron (NTBI), the iron moiety that accumulates when iron overload overwhelms the transferrin iron-binding capacity. Accordingly, ZIP14 deletion in mice ameliorates the phenotype of severe haemochromatosis, limiting extra-hepatic iron deposition (Jenkitkasemwong et al, 2015) . Cardiac iron overload due to uptake of NTBI is a dangerous complication in chronically transfused patients, such as beta-thalassaemia homozygotes. However, ZIP14 is not a candidate transporter of NTBI in cardiomyocytes. Interestingly, in a randomized trial of transfusion-dependent thalassaemic Iron is up taken by TFR1 through the endosomal cycle and, at the enterocytes apical membrane, by DMT1. The latter also participates in the endosomal cycle of TFR1 together with the reductase STEAP3. ZIP14 up takes only NTBI in conditions of iron overload. Once in the cytosol iron joins the labile iron pool and is either utilized in the mitochondria for ironsulphur (Fe/S) or haem synthesis essential for the corresponding haem (e.g. Hb) or Fe/S (e.g. IRP1) proteins production. Excess iron is stored within ferritin and recovered, if needed, through the process of ferritinophagy mediated by NCOA4 or exported by FPN. Excess haem may be exported from mitochondria through FLVCR1B and from cells through FLVCR1A. The labile iron pool is tightly regulated by the IRPs (not shown)(see text for details). FLVCR, Feline leukaemia virus C receptor; Tf, transferrin; DMT1, divalent metal transporter 1; DCYTB, duodenal cytochrome B; ZIP14, zinc transporter protein 14; NTBI, non-transferrin bound iron; FPN, ferroportin; PCBP2 = poly (rC)-binding protein; NCOA4, nuclear receptor coactivator 4; STEAP3, six-Transmembrane Epithelial Antigen of Prostate 3; TFR1, transferrin receptor; Hb, haemoglobin; IRP, iron regulatory protein; MFRN1/2, mitoferrin 1/2. patients, treatment with the calcium channel blocker amlodipine, combined with chelation therapy, reduced cardiac iron more effectively than iron chelation alone, indirectly suggesting a role for low voltage calcium channels in NTBI uptake by cardiomyocytes (Fernandes et al, 2016) . It is unknown whether ZIP proteins have a physiological role in iron uptake.
Once in the cell, iron enters the so-called Labile Iron Pool (Fig. 1) . Iron is imported into the mitochondria by mitoferrin-1, a solute carrier of the mitochondria inner membrane. In mitochondria, iron is used to synthesize haem and iron sulphur clusters, prosthetic groups of essential proteins/enzymes; in erythroblasts, iron is mainly used for haemoglobin (Hb) synthesis. In the same cells iron may also be directly transferred from endosomes to mitochondria by a 'kiss-andrun' mechanism through direct inter-organelle contacts (Hamdi et al, 2016) .
The identification of Poly (rC)-binding protein 1 (PCBP1) has provided new insights in cytosolic iron trafficking (Fig. 1) . PCBP1 is an iron chaperone that delivers iron to ferritin, the storage protein that protects cells from the redox activity of iron excess. During in vitro differentiation Pcbp1 null erythroid precursors show defects in ferritin iron flux and haem synthesis; as a result, the Pcbp1 null mouse is a model of genetic microcytic anaemia (Ryu et al, 2017) . Another iron chaperone is the poly (rC)-binding protein 2 (PCBP2), which receives iron from DMT1 or addresses iron to ferroportin for export. In addition PCBP2 binds haem oxygenase 1 and is involved in iron release from haem, connecting haem catabolism and iron recovery in macrophages (Yanatori et al, 2017) .
Ferritin has the function of safely storing excess iron. Its function is iron detoxification to avoid dangerous reactive oxygen species (ROS) generation, but also to act as a reserve and provide iron when needed. The latter process has recently been partly clarified. The Nuclear Receptor Coactivator 4 (NCOA4) is the cargo protein that directs ferritin to autophagosomes for degradation. This process, termed as 'ferritinophagy', is essential in iron deficiency to recover iron stored in ferritin for the cell needs. NCOA4 binds iron, which regulates its function at a post-translational level. In iron deficiency it binds ferritin and directs it to the autophagosomes. However, when iron is in excess, ironbound NCOA4 is recognized by the E3 ubiquitin ligase HERC2 and directed to proteasomes for degradation (Dowdle et al, 2014) (Mancias et al, 2014) . These processes are most likely essential in macrophages, which are committed to recycling or storing iron derived from red cell destruction. However, NCOA4 is highly expressed during erythropoiesis (Ryu et al, 2017) . Ferritinophagy has been suggested to contribute to haemoglobinisation of erythroblasts in cultures (Ryu et al, 2017) and to erythropoiesis of zebrafish embryos (Mancias et al, 2015) . Ncoa4-null mice do not undergo ferritinophagy, rather they accumulate ferritin, show reduced ability to recycle iron and increased susceptibility to irondeficiency anaemia (Bellelli et al, 2016) . Nevertheless, the prevalent function of NCOA4 in vivo takes place in macrophages and not in erythroid cells . NCOA4 also controls origins of DNA duplication; in vitro, its loss predisposes cells to replication stress and senescence (Bellelli et al, 2016) .
All cells may export iron through ferroportin, but the process is especially important in professional exporter cells, such as duodenal enterocytes, macrophages and hepatocytes. Ferroportin, which is highly expressed in these cells, plays an essential role in maintaining plasma iron levels ( Fig. 1 ) . Ferroportin expression is controlled at multiple levels. The ferroportin promoter contains an antioxidant response element (ARE) bound by a repressor (BACH, BTB and CNC homology protein) and an activator, NRF2 (Nuclear erythroid factor 2) . Ferroportin transcription is increased by haem through BACH inhibition, while it is suppressed by lipopolysaccharide in inflammation. In addition, binding of HIF2-a to a 5 0 Hypoxia-Response Element (HRE) enhances ferroportin expression in duodenal enterocytes (Mastrogiannaki et al, 2013) . At the translational level, a 5 0 untranslated region (UTR) iron responsive element (IRE) in SLC40A1mRNA binds iron regulatory proteins (IRPs) in conditions of low iron, repressing ferroportin protein synthesis in iron deficiency. A final posttranslational regulation is exerted by hepcidin: in addition to inducing the exporter internalization and degradation, hepcidin physically occludes the site of iron export in the central cavity of ferroportin (Aschemeyer et al, 2018) . This novel mechanism of hepcidin function was identified through an in vitro study of ferroportin mutants that do not export iron, even if not degraded by hepcidin (Aschemeyer et al, 2018) . The development of a mouse model with deregulated ferroportin activity due to hepcidin resistance (Altamura et al, 2014) has shed light on the function/activity of ferroportin in different tissues/organs.
Cellular iron regulation
The IRE/IRP machinery controls cellular iron homeostasis. The binding of IRPs to the IRE located in the UTRs of the mRNAs coding for iron-related proteins controls their expression. When the IRE is located in the 5 0 UTR, as in the H-(heavy) and L-(light) chain of ferritin, ferroportin, aminolevulinate-synthase-2 and mitochondrial aconitase, translation is inhibited by IRE-IRP binding in iron deficiency, while allowed in iron overload. In contrast, binding to 3 0 UTR IRE stabilizes TFRC and SLC11A2 mRNA when iron is low. Recent findings indicate that the two IRPs have tissue and target specificity: e.g. EPAS1 mRNA preferentially responds to IRP1. The latter also contributes to the control of erythropoietin (EPO) production in the kidney (Mastrogiannaki et al, 2013) and of iron absorption through the upregulation of DMT1, the reductase duodenal cytochrome B and ferroportin expression in duodenum. In contrast, ferritin posttranslation is prevalently regulated by IRP2 (Anderson et al, 2013 ) (Ghosh et al, 2013) . Genetic loss of both IRPs in the gut epithelium of adult mice leads to impaired iron absorption and mucosal iron retention via a ferritin-mediated mucosal block . Mice with targeted depletion of IRPs in cardiomyocytes showed a reduction in iron-sulphur cluster synthesis and mitochondria electron transport, with impaired left ventricle systolic function, defects that were rescued by intravenous iron infusions (Haddad et al, 2017) . These data support the correction of iron deficiency with intravenous iron when iron deficiency is diagnosed in chronic systolic heart failure (Ponikowski et al, 2015) .
IRPs-independent control of iron homeostasis
The mechanistic target of rapamycin (mTOR) regulates iron homeostasis in at least two ways. mTOR complex 1 (mTORC1) can control mitochondrial iron sulphur cluster biogenesis by phosphorylating the iron-sulphur cluster assembly enzyme, ISCU. ISCU protein levels indirectly inhibit IRP activity as, by acquiring iron sulphur-cluster, IRP1 is converted to aconitase, which no longer binds to IRE (Hentze et al, 2010) . In addition, mTOR controls tristetraprolin (TTP, also termed ZFP36), an RNA binding protein with anti-inflammatory properties. Low iron (a nutrient) inhibits mTOR. When the mTOR pathway is inhibited, TTP increases, binds to and induces TFRC mRNA degradation in an IRP-independently way. This mechanism of intracellular iron retention is an "iron conservation" pathway that ensures iron availability for cell survival in iron deficiency, a process conserved from yeasts to mammals (Bayeva et al, 2012) . Zfp36null mice have reduced hepcidin expression in the liver. Sirtuin 2 (SIRT2) is an iron regulated histone deacetylase that directly controls cellular iron . By binding to and deacetylating the regulator of antioxidant response, NRF2, it impairs NRF2 levels and ferroportin expression, limiting iron export. Within the "iron conservation" process SIRT2 has no effect on iron import but addresses exclusively iron export.
Novel biological functions of iron have been recently unveiled. Iron is important in the activation of the unfolded protein response (UPR), a fundamental biological mechanism conserved from yeast to humans and strongly connected with protein translation, proteasomal activity, autophagy and apoptosis. Iron modulates the clustering of IRE1, the endoplasmic reticulum stress sensor that enables UPR (Cohen et al, 2017) . Based on their findings these Authors suggested that 'iron is essential for biogenesis of haem, that in turn is a prosthetic group of enzymes of the sterol biosynthetic pathway and lipid saturation' required for the endoplasmic reticulum membrane expansion.
Recently discovered is the role of iron in ferroptosis, a form of regulated non-apoptotic cell death, mechanism of which is related to iron accumulation and is caused by lipid peroxidation (Yu et al, 2017) . Whether ferroptosis mediates cell damage in iron disorders is unclear: its role was suggested in the iron loaded hepatocytes of haemochromatosis Hfe2 (Hjv) À/ À mice, because liver damage was rescued by the ferroptosis inhibitor ferrostatin-1, but ferroptosis does not seem to play a role in the less severe Hfe À/À model .
Systemic regulation: The hepcidin/ferroportin axis
Hepcidin activation by iron
Hepcidin is mainly regulated by body iron concentration, erythropoietic drive and inflammation. Both circulating and tissue iron upregulate the expression of hepcidin through the activation of the Bone morphogenetic proteins/Small mother against decapentaplegic (BMP/SMAD) signalling by BMP ligands (Babitt et al, 2006; Healey et al, 2015) . The activation of the pathway requires a crosstalk between different types of liver cells. BMPs are members of the transforming growth factor beta superfamily and are mainly produced by Liver Sinusoidal Endothelial Cells (LSEC). In mice Bmp6 mRNA expression increases in parallel with iron in liver non-parenchymal cells (Enns et al, 2013; Rausa et al, 2015) to activate hepcidin in hepatocytes with a paracrine mechanism. How BMP6 is regulated by iron remains to be defined. A role in mice has been suggested for NRF2 (Lim et al, 2018) , which controls the expression of antioxidant response genes. In this context, the activation of BMP6 by iron would be indirect, through ROS-induced NRF2, in a homeostatic circuit that limits one trigger (iron) of ROS formation. The function of angiocrines, molecules produced by the vascular wall, may differ in different organs. The angiocrine BMP2 is known to be involved in bone and cartilage development; however, a recently recognized ligand of BMP receptors has recently been found in the liver. Selective LSEC inactivation of Bmp2 leads to insufficient hepcidin production and iron overload in mice (Canali et al, 2017a; Koch et al, 2017) . BMP2 and BMP6 functions are not redundant, as neither of the two cytokines compensates the lack of the other in KO mice. In addition, inactivation of Bmp2 (not of other Bmps) by antibodies both in wild type and in Bmp6 À/À mice reduces hepcidin and increases liver iron overload (Canali et al, 2017b) . BMP2 is expressed at remarkably higher levels than BMP6 in basal conditions, while BMP6 expression approaches the BMP2 levels in response to iron excess (Canali et al, 2017b) . Whether BMP2-BMP6 heterodimeric ligands also activate hepcidin remains to be defined. The relevance of the BMP pathway is strengthened by the phenotype of iron overload and low hepcidin caused by the inactivation of different components of the pathway: BMP6, Hemojuvelin (HJV), type I bone morphogenetic protein receptor (BMPR) as activin receptor-like kinase-2 and 3 [ALK2 (ACVR1) and ALK3 (BMPR1A)] (Steinbicker et al, 2011) , type II BMPR, SMAD4 (Wang et al, 2005) , SMAD1-5 (Canali et al, 2016) and BMP2 proteins (Canali et al, 2017b; Koch et al, 2017) .
Chronic treatment with iron induces Bmp6 expression and increases hepcidin in all haemochromatosis murine models. However, a single oral iron dose that increases exclusively transferrin saturation and not liver iron concentration does not augment hepcidin in haemochromatosis patients with mutations in transferrin receptor 2 (TFR2) , nor in Tfr2 À/À and Hfe2 À/À mice (Ramos et al, 2011) . Considering that the phenotype of Acvr1 À/À mice is less severe than that of Bmpr1a À/À (Steinbicker et al, 2011) HJV-ALK3 might provide the basal hepcidin activation, probably triggered by BMP2, while the ALK2-mediated iron response would be determined by BMP6 (Colucci et al, 2017) . The existence of two branches of the BMP/SMAD pathway of hepcidin activation was first hypothesised based on the residual ability to enhance hepcidin and SMAD phosphorylation in response to iron in Bmp6 À/À mice. It was also confirmed by the gender diversity and phenotype severity of mice KO for both Bmp6 and the haemochromatosis genes (Bmp6-Hfe and Bmp6-Tfr2 double KO) (Latour et al, 2016) and Bmp6-Hfe2 double KO (Latour et al, 2017) .
Hepcidin activation in inflammation
Hepcidin, as an anti-microbial peptide, is increased in inflammation/infections by pro-inflammatory cytokines, especially by interleukin 6 (IL-6) that binds IL-6 receptors and activates STAT3 (Hentze et al, 2010) . High hepcidin levels contribute to anaemia of inflammation, which is characterized by iron sequestration in macrophages, decreased iron absorption and iron restricted erythropoiesis (Weiss & Goodnough, 2005) . The full activation of the hepcidin pathway by inflammation requires active BMP signalling and SMAD4 (Wang et al, 2005) indicating that BMP/SMAD signalling is a potential target to decrease hepcidin also in inflammatory conditions.
Hepcidin inhibition
Hepcidin expression is suppressed in iron deficiency, hypoxia and erythropoietic expansion (stress erythropoiesis). Welldefined hepcidin inhibitors are the liver protease matriptase 2, encoded by the transmembrane serine protease 6 (TMPRSS6) gene and the erythroid-released hormone, erythroferrone (ERFE). In iron deficiency, matriptase 2 inhibits hepcidin by cleaving the BMP co-receptor HJV on the hepatocyte membrane (Silvestri et al, 2008) . Cleavage of other substrates, as recently proposed (Wahedi et al, 2017) , seems unlikely, at least for the HFE and TFR2 genes. Indeed double KO for each of these genes and Tmprss6 show the same phenotype (iron deficiency with high hepcidin) of Tmprss6 KO alone, leading to the conclusion that TFR2 and HFE act upstream of TMPRSS6 (Finberg et al, 2011) (Nai et al, 2014) and suggesting that they are not the protease substrates. By contrast, the iron overload phenotype observed in Tmprss6-Hfe2 double KO mice places the TMPRSS6 site of action upstream of HJV, compatible with the HJV being the protease substrate (Finberg et al, 2011) . TMPRSS6 is present on the cell surface (Zhao et al, 2015) in iron deficiency and in hypoxia (Hentze et al, 2010) . TMPRSS6 mutations cause the rare genetic iron deficiency anaemia refractory to oral iron supplementation (IRIDA), characterized by inappropriately high hepcidin levels both in mice (Du et al, 2008) and in humans (De Falco et al, 2014) (Finberg et al, 2008) . TMPRSS6 single nucleotide polymorphisms have been associated with mean cell volume and mean cell haemoglobin variations in genome wide association studies in the general population and also with iron deficiency in some ethnic groups (for review see (Camaschella, 2017) ).
ERFE is a member of the C1q/tumour-necrosis factorrelated protein family, previously reported as Fam132b or myonectin, a muscle secreted protein with a role in lipid regulation (Seldin et al, 2012) . Erfe is an EPO target gene activated by Janus Kinase 2-Signal transducer and activator of transcription 5and, though widely expressed, is increased by EPO only in the erythropoietic (bone marrow and spleen) tissues. In mice, Erfe expression increases as soon as 4 h after phlebotomy or EPO treatment, while hepcidin is suppressed at 9-12 h .
The phenotype of Erfe À/À mice is mild: while young animals have mild iron deficiency anaemia during rapid growth, both Hb and iron are normal in adult mice. In the same animals after phlebotomy, anaemia persists longer and recovery is delayed, because they fail to suppress hepcidin as wild type mice do. Nevertheless, in the long term, Erfe À/À animals compensate anaemia, suggesting the existence of other regulators. ERFE also helps recovery of anaemia in acute inflammation, given that suppressing hepcidin favours iron acquisition . All these observations strengthen the role of ERFE in stress erythropoiesis. TMPRSS6 has a dominant effect over ERFE. Indeed ERFE is unable to suppress the high hepcidin levels of Tmprss6 À/À mice . Consistent with this, the inactivation of Tmprss6 in beta-thalassaemia Hbb th3/+ mice prevents iron overload and partially corrects the anaemic phenotype (Nai et al, 2012; Guo et al, 2013; Schmidt et al, 2013) , whereas, Erfe deletion in the same beta-thalassaemia mice reduces iron overload without correcting anaemia (Kautz et al, 2015) . The mechanism of ERFE inhibition of hepcidin is unclear, but appears to act through the SMAD pathway, because hepcidin is not suppressed by EPO in Smad1, Smad5 double KO mice (Canali et al, 2016) . Another regulator of hepcidin is platelet-derived growth factor-BB (PDGF-BB), produced in hypoxia by several cell types: PDGF-BB suppresses hepcidin transcription in vivo in mice and in healthy volunteers undergoing hypoxia, through (Sonnweber et al, 2014) .
Interestingly, hepcidin suppression requires histone deacetylase 3, which, when bound at the hepcidin locus induces reversible epigenetic modifications, both in iron deficient and erythropoietin-stimulated erythropoiesis (Pasricha et al, 2017) .
A novel hepcidin inhibitor is the FK506-binding protein peptidyl-prolyl-cis/trans-isomerase (FKBP12), a molecule known to complex with rapamycin to inhibit mTORC1. FKBP12 binds the glycine-serine rich domain of ALK2 receptor, suppressing its activation (Colucci et al, 2017) , accounting for previous observations that rapamycin increases hepcidin expression (Mleczko-Sanecka et al, 2014). The inhibition of type 1 BMPR by FKBP12 is HJV independent (Colucci et al, 2017) that may be consistent with the dual BMP pathway arms, as proposed (Latour et al, 2016) .
Testosterone also inhibits hepcidin (Latour et al, 2014) , a process that favours the higher Hb levels produced by male erythropoiesis.
The erythropoiesis/hepcidin crosstalk
The iron needs of erythropoiesis are primarily sustained by macrophages that in adults recycle iron (20-25 mg/day) derived from senescent erythrocyte breakdown. Transferrin provides iron to the TFR1 endosomal cycle and its percent saturation inversely reflects the iron consumed in erythropoiesis. Diferric transferrin is also a ligand of TFR2 and a signal for hepcidin increase.
The body exerts a tight control not to waste iron and at the same time to protect cells from iron toxicity. A liver population of macrophages is an example of this retention and protection double mechanism: in haemolytic states, such as sickle cell anaemia and anaemia of inflammation, a transient population of macrophages appear that phagocytose abnormal red cells, differentiate into iron exporter macrophages and release iron to the circulation, preventing liver (and kidney) damage caused by iron or haem excess (Theurl et al, 2016) .
Bone marrow macrophages may play a role in erythropoiesis, favouring erythroblast maturation within the erythroblast islands. In vitro, macrophages release iron in the form of ferritin to maturing cells, although whether this phenomenon is important in vivo is unclear. Macrophages assist the enucleation process of orthochromatic erythroblasts, a process controlled by iron availability .
The discovery of ERFE was a milestone in the crosstalk between erythropoiesis and iron, providing the experimental proof to the old concept of "erythroid regulator" proposed by Finch (1994) . ERFE explains how erythropoiesis asks for iron, inhibiting the expression of hepcidin.
However, erythropoiesis is also adjusted to the available iron by erythroid TFR2. Primarily identified for its function of circulating iron sensor, hepcidin activator and as the gene of type 3 haemochromatosis (Camaschella et al, 2000) (Table I) , TFR2, which is homologous to TFR1, is highly expressed in erythroid cells. Here it interacts with EPO receptor (EPOR) on the cell surface (Forejtnikova et al, 2010) . We selectively deleted Tfr2 in erythroid cells by transplanting bone marrow cells from a Tfr2 null donor into a lethally irradiated wild type recipient . The resulting erythrocytosis and increased Hb levels in mice without bone marrow TFR2 in the presence of normal serum EPO suggest that, in the absence of TFR2, EPO signalling is overactive. Consistent with this interpretation, the expression of EPO target genes, including ERFE, is increased. Thus, sensing increased circulating iron, on one side TFR2 acts as a brake on EPO signalling to avoid excessive erythroid expansion and on the other, by upregulating hepcidin, preserves iron homeostasis . By limiting erythropoiesis TFR2 also restricts ERFE production, favouring hepcidin expression and restricting iron acquisition (Fig. 2) . Recent data indicate that in early erythroid progenitors both TFR2 and EPOR might be bound by scribble, a receptor regulator that would serve the delivery of both proteins to cell surface (Khalil et al, 2018) . How these in vitro data can be reconciled with our in vivo results remains to be investigated.
The erythropoiesis -liver crosstalk is an example of hepcidin regulation by a specific tissue. It is reasonable to speculate that other regulators are released to signal specific needs of different tissues (e.g. from iron-deficient muscles). Alternatively, iron could be handled locally: an example is the hepcidin-ferroportin axis that regulates cardiomyocytes iron independently of systemic hepcidin (Lakhal-Littleton et al, 2016) .
Clinical implications of basic research
The impressive advances in our knowledge of iron metabolism have translational implications for the diagnosis and treatment of iron disorders. This large group of pathological condition includes both genetic and acquired disorders, as classified in Table I . There are several forms of iron deficiency, which may be 'absolute' when total body iron is decreased, and 'relative' or 'functional' when iron requirements exceed iron supply. This occurs in anaemia of chronic inflammation because of hepcidin-induced iron sequestration in stores, as well as secondary to the use of erythropoiesisstimulating agents that acutely increase the iron needs of the erythron in a way disproportionate to the available iron. In addition, there are rare genetic forms of iron deficiency that are accompanied by tissue iron accumulation . Iron overload may occur in genetic disorders as the different types of haemochromatosis or be secondary to increased iron absorption, as in ineffective erythropoiesis, chronic blood transfusions or liver disorders, all conditions that affect the hepcidin pathway.
Implications for diagnosis
The availability of assays to quantify hepcidin and, more recently, ERFE in patient serum raises the question of their usefulness as markers of iron status and/or erythropoiesis efficiency. An analysis of the most promising clinical settings in which hepcidin measurement might be of value has been reported (Girelli et al, 2016) . It should be recognised that the hormone responds to different stimuli and that the response is rapid: thus, besides a circadian rhythm (Troutt et al, 2012) , its levels may undergo dynamic changes. Several assays are available, the most important being based on mass spectrometry (which measures the mature 25 amino acid peptides) or on classical immunoassays (which can measure the different hepcidin isoforms) (Girelli et al, 2016) . Independently of gender, hepcidin is almost undetectable in absolute iron deficiency (Traglia et al, 2011) , where its measurement has no added value over low serum ferritin. The exception is genetic iron deficiency (IRIDA). Here, hepcidin levels are normal/high, in any case being inappropriate to the very low circulating iron. Hepcidin production is also low in chronic inflammatory disorders associated with iron deficiency, provided that the latter is severe; however, whether its assay can be used to discriminate iron deficiency in the setting of inflammation remains uncertain. In specific contexts hepcidin concentration has been proposed as a guide to oral iron supplementation: in studies that used iron isotopes to define iron absorption, low serum hepcidin predicted the efficacy of iron treatment in African children with concomitant severe infections (Prentice et al, 2012; Pasricha et al, 2014) . Some small studies have used hepcidin as a predictor of poor iron responsiveness to oral supplementation and of the necessity to switch to intravenous iron (Prentice et al, 2012; Bregman et al, 2013) . However, larger studies are needed and the test should be compared to other proposed predictive haematological parameters (van Santen et al, 2014) .
Hepcidin normally correlates strongly with serum ferritin. In iron overload the ratio hepcidin/ferritin may define the appropriateness of hepcidin levels (Girelli et al, 2016) . All types of haemochromatosis are characterized by inefficient hepcidin response to iron overload. However, hepcidin can be decreased by other factors, such as alcohol or defective liver function. Where the hormone levels are low, the evaluation must be accompanied by liver function tests, and where they are high, C-reactive protein and kidney function tests must be performed (Girelli et al, 2016) . A first-generation immunoassay to measure human circulating erythroferrone (hERFE) has been developed. After EPO treatment, as well as after donating 2 units of blood by apheresis, serum ERFE increases, reaching a maximum within a week; in beta-thalassaemia patients, it is remarkably high and inversely correlates with hepcidin levels, but, as expected, it is reduced after blood transfusions . The assay is currently used for research purposes to evaluate the erythropoiesis-hepcidin connection in different physiological settings and pathological conditions. Experience with ERFE assay is still limited; it will be of interest to test its diagnostic value in disorders of erythropoiesis. In theory, its increase could be a marker of erythropoiesis expansion, but whether it performs well and/or is a more accurate marker of global erythropoiesis than soluble TFR, remains to be assessed.
Implications for treatment
Iron deficiency. The first line treatment for chronic iron deficiency is usually oral iron. Only a small proportion of the iron is absorbed and, unfortunately, the effect of nonabsorbed iron on the gut mucosa sometimes results in gastrointestinal adverse effects. The reduced tolerability and the need for prolonged treatment may reduce patient compliance to oral iron therapy. The rapid response of hepcidin to oral Table II . Proposed targeted therapeutic approaches in primary and secondary iron overload and in ineffective erythropoiesis. [Adapted from ASO, allele-specific oligonucleotide; DFP, deferiprone; Hb, haemoglobin; JAK2, Janus kinase 2; siRNA, short interfering RNA; TMPRSS6, Transmembrane serine protease 6. All references quoted in Table II are reported in Appendix S1. *Hepcidin is now entering clinical trials. †Also used in a clinical trial phase 2a on both non-transfusion dependent and transfusion dependent-thalassaemia patients (Taher et al, 2018) .
iron supplementation was used in two studies to define the best schedule for oral iron administration. Clinical trials in non-anaemic iron-deficient young women using stable iron isotopes have shown that iron salts (iron sulphate 60-240 mg) cause hepcidin to increase for at least 48 h, limiting the efficacy of further therapy (Moretti et al, 2015) . The results suggest that iron administration may be more efficient using a single 60 mg dose on alternate days (Stoffel et al, 2017) . Such a protocol also increases tolerability, reducing gastrointestinal side effects and may be advisable in iron deficient non-anaemic patients. The relatively low dose will also decrease the negative effect of non-absorbed iron on the intestine microbiome (Lee et al, 2017) . High hepcidin levels explain cases of resistance to pharmacological iron compounds, a lesson learned from patients affected by IRIDA, who usually require intravenous iron (Finberg et al, 2011) . The use of intravenous iron has increased in recent years, due to increased safety of the compounds and to the availability of preparations suitable for administration at high dose in a single infusion (Camaschella, 2015) . A better response to intravenous as compared to oral iron has been documented in chronic kidney disease (CKD), especially in association with erythropoiesis-stimulating agents (Macdougall et al, 2014) that induce a relative iron deficiency. Also, oral iron does not perform well in patients with chronic heart failure and iron deficiency (Lewis et al, 2017) . Considering that intravenous iron preparations mainly accumulate in reticuloendothelial cells, it is reasonable to hypothesize that high intracellular iron in macrophages relieves the IRP block on ferroportin translation, as discussed under ferroportin regulation. Higher ferroportin activity would be expected to counteract the block in macrophage iron mobilization caused by high hepcidin levels.
There is interest in forms of iron that are absorbed independently from the hepcidin pathway: candidates are iron/ haem oral preparations (liposomal iron, haem iron polypeptide, iron-based phosphate binders), especially developed for CKD patients. However, at present the evidence of clinical benefit is limited and experimental evidence of the alternative absorption mechanism is lacking. In search of novel approaches, the small molecule natural compound hinokitiol has been reported to restore iron transport in cells lacking different iron transporters, such as the iron importer DMT1, the mitochondrial importer mitoferrin and the exporter ferroportin (Grillo et al, 2017) . Hinokitiol may restore iron transport by exploiting the iron gradient that is formed across the membrane, when a physiological transporter is inactive, as shown in intestinal CACO2 cells lacking DMT1. Besides these in vitro experiments, positive effects on iron absorption were demonstrated in zebrafish and also in mice Left panel represents a condition with high serum diferric transferrin: in the upper part a maturing bone marrow erythroblast is shown. By binding diferric transferrin, TFR2 is stabilised on the plasma membrane, where it associates with erythropoietin receptor (EPOR) to reduce signalling from EPO (dotted red line) and suppress erythroferrone (ERFE) production. In the lower part, binding of diferric transferrin to TFR2 on the plasma membrane of hepatocytes forms part of the complex that controls hepcidin expression. Right panel represents a condition with low diferric transferrin as in iron deficiency. Apotransferrin does not bind with TFR2, which, as a consequence, is not stabilized on the plasma membrane of both cell types: erythropoietin signalling is increased and ERFE is produced. Circulating ERFE and lack of membrane TFR2 suppress hepcidin expression in hepatocytes. BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein receptor; EPO, erythropoietin; EPOR, erythropoietin receptor; ERFE, erythroferrone; HAMP, hepicidin gene; HFE, haemochromatosis type 1 gene; HJV, haemojuvelin; SMAD, small mother against decapentaplegic; Tf, transferrin; TFR2, transferrin receptor 2. in an acute setting (Grillo et al, 2017) . However, a persistent effect in the latter has not been documented yet.
Iron overload. Manipulation of the hepcidin pathway is a proposed therapeutic strategy in diseases leading to iron overload. The approach of increasing hepcidin prevents iron overload or at least redistributes iron to macrophages for safe storage. Although potentially useful for all types of iron overload, hepcidin agonists might be relevant in iron loading anaemias , where iron overload is secondary to ineffective erythropoiesis. Several compounds counteract iron overload and partially correct anaemia in preclinical studies of beta-thalassaemia, and a few are entering phase 1 clinical trials (Table II) . The approach is based on the use of hepcidin agonists (hepcidin peptide or hepcidin mimics), agents that inhibit hepcidin inhibitors (e.g., anti-TMPRSS6 molecules) or compounds that interfere with the hepcidin effect on ferroportin. Administration of exogenous hepcidin controls iron in polycythaemia vera models, a condition that benefits from iron restriction (Casu et al, 2016) . It can be foreseen that some compounds will become, at least, disease modifiers in thalassemia, probably used in combination with drugs that affect erythroid differentiation and act via different mechanisms, such as the activin ligand traps (Dussiot et al, 2014) . The latter, now in a phase 3 clinical trial, have been shown to increase Hb in non-transfusion-dependent thalassaemic patients and to decrease transfusion requirement in a proportion of transfusion-dependent patients.
In contrast, hepcidin antagonists have been proposed to treat anaemia of inflammation that is accompanied by a high hepcidin, as a result of upregulation by proinflammatory cytokines. Selected hepcidin-antagonists, such as monoclonal antibodies, L-RNA aptamers, anticalins and non-anticoagulant heparins, have been developed to downregulate hepcidin; another approach is to target the BMP pathway, as it is essential for full hepcidin activation (for review of all approaches see (Crielaard et al, 2017) ). However, targeting hepcidin alone may not be sufficient, because hepcidin is only one component of the complex array of mechanisms leading to anaemia of inflammation, the control of which will probably require additional interventions.
The screening of drugs already approved for clinical use based on the results of a genome-wide RNA interference screening for hepcidin regulators identified rapamycin as a hepcidin activator and spironolactone and imatinib as hepcidin suppressors in primary hepatocytes and in murine models (MleczkoSanecka et al, 2017) . It is expected that the repurposing strategy will discover other commercial drugs to be tested in iron/erythroid disorders.
Conclusions
We are living a new iron era: novel targeted and more personalised approaches are proposed and tested in iron disorders, based on advances of both basic science and the results of preclinical testing. That notwithstanding, several questions remain to be clarified, including how the multiple regulators of hepcidin integrate, how hepcidin interacts with cell and tissue regulators, why different organs have different sensitivity to iron toxicity, how iron influences the immunological responses, which is the role of iron in malignancies and in common chronic degenerative diseases, such as atherosclerosis and neurodegeneration. In clinical terms we have to understand better how iron is handled outside erythropoiesis and how to diagnose iron deficiency in the absence of anaemia. As for treatment, we must clearly define which is the best schedule for oral iron administration and provide clearer indications to intravenous iron treatment. The possibility of developing compounds effective for humans and not for microorganisms is another central challenge to control iron deficiency in developing countries.
Further progress in basic research and further clinical studies will increase the treatment opportunities for patients: in the near future we hopefully will learn how to tailor ironrelated treatments (iron supplementation, inducers of iron redistribution or iron depletion, isolated or in combination) to individuals, according to different pathological conditions and specifically considering age, gender, and complex clinical circumstances.
